Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Data on cancer vaccines described by researchers at Center of Molecular Immunology
October 8th, 2008
Investigators publish new data in the report 'Priming and boosting determinants on the antibody response to an Epidermal Growth Factor-based cancer vaccine.' "Epidermal Growth Factor chemically conjugated to P64k carrier protein from Neisseria meningitidis emulsified in Montanide ISA 51 adjuvant is a cancer vaccine under clinical evaluation. We explored the influence of priming and boosting variables on the antibody response in mice," scientists in Havana, Cuba report. "An apparently low dose fractionated in multiple anatomical sites at priming accelerated the induction and enhanced the maximal antibody response, with a long-lasting effect. Moreover, shortening...
Source: Vaccine Weekly (2008-10-08)
|
